{"id":"hbm9161-injection-680mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HBM9161 targets programmed death ligand 1 (PD-L1), a checkpoint protein that tumors use to evade immune surveillance. By blocking PD-L1, the drug restores T-cell activation and proliferation, allowing the immune system to recognize and attack cancer cells. This mechanism is characteristic of immune checkpoint inhibitors used across multiple cancer types.","oneSentence":"HBM9161 is a monoclonal antibody that blocks the interaction between PD-L1 and its receptors to enhance anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:51.388Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation)"}]},"trialDetails":[{"nctId":"NCT05332210","phase":"PHASE3","title":"Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis","status":"UNKNOWN","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","startDate":"2022-06-30","conditions":"Myasthenia Gravis","enrollment":144},{"nctId":"NCT04346888","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients","status":"COMPLETED","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","startDate":"2020-07-23","conditions":"Myasthenia Gravis","enrollment":30},{"nctId":"NCT05039190","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients","status":"COMPLETED","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","startDate":"2021-09-25","conditions":"Myasthenia Gravis","enrollment":132},{"nctId":"NCT05015127","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease","status":"UNKNOWN","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","startDate":"2021-09-22","conditions":"Thyroid Ophthalmopathy","enrollment":36},{"nctId":"NCT04227470","phase":"PHASE1","title":"A Study of HBM9161 in NMOSD Patients","status":"COMPLETED","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","startDate":"2020-03-31","conditions":"NMO Spectrum Disorder","enrollment":9},{"nctId":"NCT03971916","phase":"PHASE1","title":"A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","startDate":"2019-06-03","conditions":"Healthy Chinese Volunteers","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HBM9161 Injection (680mg)","genericName":"HBM9161 Injection (680mg)","companyName":"Harbour BioMed (Guangzhou) Co. Ltd.","companyId":"harbour-biomed-guangzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HBM9161 is a monoclonal antibody that blocks the interaction between PD-L1 and its receptors to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}